CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01631552
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:04.336475+00:00
Published At: 2021-04-06T00:00:00+00:00
Record Updated At: 2021-08-12
Results Posted At: 2021-04-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Gastric Adenocarcinoma", "Esophageal Cancer", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Ovarian Epithelial Cancer", "Carcinoma Breast Stage IV", "Hormone-refractory Prostate Cancer", "Head and Neck Cancers- Squamous Cell", "Renal Cell Cancer", "Urinary Bladder Neoplasms", "Cervical Cancer", "Endometrial Cancer", "Glioblastoma Multiforme", "Triple Negative Breast Cancer", "Pancreatic Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-08-12"
protocolSection.identificationModule.nctId: "NCT01631552"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2021-04-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.